No headlines found.
No press releases found.
No news found.
Rezera Inc is a clinical-stage biotechnology company developing a portfolio of internally invented, proprietary and wholly owned oral inhibitors of NLRP3. NLRP3 is the upstream driver of sterile inflammation - inflammation that is caused by damage signals, such as cholesterol crystals or misfolded proteins.
Rezera trades on the NASDAQ stock market under the symbol RZRA.
As of November 12, 2026, RZRA stock price was flat at $0.00 with million shares trading.
RZRA has a market cap of $0.00. This is considered a Sub-Micro Cap stock.
